Table 4.
Other COVID-19 vaccines in the clinical trial.
| Name | Company | Location | Vaccine type | Phase | |
|---|---|---|---|---|---|
| 1 | CoronaVac | Sinovac | China | Inactivated virus | Phase Ⅳ ChiCTR2100052697 |
| 2 | COVID-19 Vaccine (Vero Cell), Inactivated | Wuhan Institute of Biological Products | China | Inactivated virus | Phase Ⅲ ChiCTR2000034780 |
| 3 | Sinopharm COVID-19 vaccine | Beijing Institute of Biological Products | China | Inactivated virus | Phase Ⅱ ChiCTR2000032459 |
| 4 | Inactivated ASRS-CoV-2 vaccine | Chinese Academy of Medical Science | China | Inactivated virus | Phase Ⅱ NCT04412538 |
| 5 | BBV152 | Bharat Biotech International Limited | India | Inactivated virus | Phase Ⅱ NCT04471519 |
| 6 | AG0301-COVID19 | AnGes, Inc. | Japan | DNA | Phase Ⅱ NCT04463472 |
| 7 | ZyCoV-D | Zydus Cadila | India | DNA | Phase Ⅱ CTRI/2020/07/026352 |
| 8 | GX-19 | Genexine, Inc. | Korea | DNA | Phase Ⅱ NCT04445389 |
| 9 | INO-4800 | International Vaccine Institute | Korea | DNA | Phase Ⅱ NCT04447781 |
| 10 | AZD1222 | AstraZeneca | Russian | Viral vector | Phase Ⅲ NCT04540393 |
| 11 | Ad26.COV2.S | Janssen Vaccines & Prevention B.V. | America | Viral vector | Phase Ⅱ NCT04436276 |
| 12 | Gam-COVID-Vac Lyo | Gamaleya Research Institute of Epidemiology and Microbiology | Russian | Viral vector | Phase Ⅱ NCT04437875 |
| 13 | Gam-COVID-Vac | Gamaleya Research Institute of Epidemiology and Microbiology | Russian | Viral vector | Phase Ⅱ NCT04436471 |
| 14 | Ad5-nCoV | CanSino Biological Inc. | China | Viral vector | Phase Ⅲ ChiCTR2100044249 |
| 15 | GRAd-COV2 | ReiThera Srl | Italy | Viral vector | Phase Ⅲ NCT04791423 |
| 16 | TMV-083 | Institut Pasteur | Belgium | Viral vector | Phase Ⅰ NCT04497298 |
| 17 | SCB-2019 | Clover Biopharmaceuticals AUS Pty Ltd | Australia | Recombinant protein | Phase Ⅰ NCT04405908 |
| 18 | Covax-19 | Vaxine Pty Ltd | Australia | Recombinant protein | Phase Ⅰ NCT04453852 |
| 19 | UQ-1-SARS-CoV-2-Sclamp | Queensland/CSL/Seqirus | Australia | Recombinant protein | Phase Ⅰ NCT04495933 |
| 20 | Recombinant new CoV vaccine (CHO cell) | Anhui Zhifei Longcom Biopharmaceutical Inc | China | Recombinant protein | Phase Ⅱ NCT04466085 |
| 21 | MVC-COV1901 | Medigen Vaccine Biologics Corp. | Taiwan, China | Recombinant protein | Phase Ⅰ NCT04487210 |
| 22 | SARA-CoV-2 rS | Novavax | America | Recombinant protein | Phase Ⅱ NCT04368988 |
| 23 | Covac 1 | University Hospital Tübinge | German | Peptide | Phase Ⅰ NCT04546841 |
| 24 | CoVLP | Medicago | Canada | Virus-like particles (VLP) | Phase Ⅰ NCT04450004 |
Administration route: all intramuscular
Details may be found at the website in the supplementary material